Insulet Corporation $PODD Stock Holdings Raised by Tredje AP fonden

Tredje AP fonden lifted its stake in shares of Insulet Corporation (NASDAQ:PODD) by 39.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 8,901 shares of the medical instruments supplier’s stock after buying an additional 2,514 shares during the quarter. Tredje AP fonden’s holdings in Insulet were worth $2,748,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Norges Bank acquired a new stake in Insulet during the second quarter valued at approximately $324,689,000. Qube Research & Technologies Ltd bought a new stake in shares of Insulet in the 2nd quarter valued at approximately $131,439,000. Worldquant Millennium Advisors LLC acquired a new stake in shares of Insulet during the 2nd quarter valued at approximately $80,082,000. Munro Partners lifted its stake in Insulet by 1,483.0% during the third quarter. Munro Partners now owns 227,240 shares of the medical instruments supplier’s stock worth $70,156,000 after purchasing an additional 212,885 shares during the last quarter. Finally, AustralianSuper Pty Ltd boosted its holdings in Insulet by 487.5% in the second quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock worth $64,460,000 after purchasing an additional 170,247 shares during the period.

Insulet Stock Performance

PODD opened at $241.89 on Friday. Insulet Corporation has a twelve month low of $230.05 and a twelve month high of $354.88. The stock has a market cap of $17.03 billion, a PE ratio of 69.11, a price-to-earnings-growth ratio of 1.50 and a beta of 1.41. The business’s 50 day moving average is $272.44 and its 200-day moving average is $304.96. The company has a current ratio of 2.81, a quick ratio of 2.18 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm had revenue of $783.80 million for the quarter, compared to the consensus estimate of $768.31 million. During the same quarter in the previous year, the business earned $1.15 EPS. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on PODD shares. Barclays restated an “underweight” rating and issued a $286.00 price target on shares of Insulet in a research report on Thursday. Sanford C. Bernstein cut their target price on shares of Insulet from $380.00 to $330.00 and set an “outperform” rating on the stock in a report on Thursday. TD Cowen downgraded Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price for the company. in a research note on Monday, January 26th. Leerink Partners dropped their price target on Insulet from $386.00 to $360.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Canaccord Genuity Group cut their price target on Insulet from $450.00 to $435.00 and set a “buy” rating on the stock in a report on Wednesday. Twenty equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $354.57.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported a strong Q4: revenue and EPS beats, margin expansion, record Omnipod growth and a bullish 2026 outlook; management also expanded the share‑repurchase program — these operational wins drove the initial post‑earnings rally. Insulet Posts Strong Q4 Results, Expands Share Repurchase Program
• Positive Sentiment: Street reaction includes buy/overweight/outperform reiterations (BTIG reiterated Buy) and headlines noting a gap‑up after the earnings beat, which supported intraday upside earlier this week. BTIG Research Reiterates “Buy” Rating for Insulet Insulet Shares Gap Up Following Earnings Beat
• Neutral Sentiment: Reported short‑interest data is effectively zero/erroneous (0 shares), so there’s no clear short‑squeeze dynamic in play based on the available figures.
• Negative Sentiment: Multiple firms trimmed price targets this week (Raymond James to $355, Citigroup to $345, JPMorgan to $340, Leerink to $360). Although these firms mostly kept Buy/Outperform ratings, the lower targets remove some upside expectations and likely contributed to today’s pullback. Raymond James Adjusts Insulet Price Target Benzinga coverage of analyst target changes

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.